Calcitonin gene-related peptide analogues with aza and indolizidinone amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor

Journal of Medicinal Chemistry

Volumn 50, Issue 6, 2007, Pages 1401-1408

  Boeglin, Damien ^a   Hamdan, Fadi F ^a   Melendez, Rosa E ^a   Cluzeau, Jérôme ^a   Laperriere, Andre ^a   Heroux, Madeleine ^a   Bouvier, Michel ^a   Lubell, William D ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 3 AMINOINDOLIZIDIN 2 ONE DERIVATIVE; 9 OXO 8 AMINO 4 PHENYLINDOLIZIDIN 9 ONE DERIVATIVE; 9 OXO 8 AMINOINDOLIZIDIN 9 ONE DERIVATIVE; AMINO ACID DERIVATIVE; CALCITONIN GENE RELATED PEPTIDE 1 RECEPTOR; CALCITONIN GENE RELATED PEPTIDE DERIVATIVE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; INDOLIZIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG INDICATION; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; INFLAMMATION; MIGRAINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PEPTIDE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; AMINO ACIDS; AZA COMPOUNDS; CALCITONIN GENE-RELATED PEPTIDE; CELL LINE; CYCLIC AMP; HUMANS; INDOLIZINES; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33947674064     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061343w     Document Type: Article

References (83)

1. Amara, S. G.; Jonas, V.; Rosenfeld, M. G.; Ong, E. S.; Evens, R. M. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptides products. Nature 1982, 298, 240-244.
2. Steenberg, P. H.; Hoppener, J. W. M.; Zandberg, J.; Van de Yen, W. J. M.; Jansz, H. S.; Lips, C. J. M. A second calcitonin/CGRP gene. FEBS Lett. 1985, 183, 403-407.
3. Van Rossum, D.; Hanisch, U. K.; Quirion, R. Neuroanatomical localization, pharmacological caracterization and functions of CGRP, released peptides and their precursors. Neurosci. Biobehav. Rev. 1997, 21, 649-678.
4. Di Angelantonio, S.; Giniatullin, R.; Costa, V.; Sokolova, E.; Nistri, A. Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells. Br. J. Pharmacol. 2003, 139, 1061-1073.
5. Dennis, T.; Fournier, A.; St Pierre, S.; Quirion, R. Structure-activity profile of calcitonin gene-related peptide in peripheral and brain tissues. Evidence of receptor multiplicity. J. Pharmacol. Exp. Ther. 1989, 251, 718-725.
6. Mimeault, M.; Fournier, A.; Dumont, Y.; St Pierre, S.; Quirion, R. Comparative affinities and antagonistic potencies of various human CGRP fragments on CGRP receptors in brain and periphery. J. Pharmacol. Exp. Ther. 1991, 258, 1084-1090.
7. Poyner, D. R.; Sexton, P. M.; Marshall, I.; Smith, D. M.; Quirion, R.; Born, W.; Muff, R.; Fischer, J. A.; Foord, S. M. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 2002, 54, 233-246.
8. Husmann, K.; Born, W.; Fischer, J. A.; Muff, R. Three receptor-activity-modifying proteins define calcitonin gene-related peptide or adrenomedullin selectivity of the mouse calcitonin-like receptor in COS-7 cells. Biochem. Pharmacol. 2003, 66, 2107-2115.
9. Foord, S. M.; Marshall, F. H. RAMPs: accessory proteins for seven transmenbrane domain receptors. Trends Pharmacol. Sci. 1999, 20, 184-187.
10. Mc Latchie, L. M.; Fraser, N. J.; Main, M. J.; Wise, A.; Brown, J.; Thompson, N.; Solari, R.; Lee, M. G.; Foord, S. M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393, 333-339.
11. Evans, B. N.; Rosenblatt, M. I.; Mnayer, L. O.; Oliver, K. R.; Dickerson, I. M. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem. 2000, 275, 31438-31443.
12. Ma, W.; Chabot, J. G.; Powell, K. J.; Jhamandas, K.; Dickerson, I. M.; Quirion, R. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience 2003, 120, 677-694.
13. Yallampalli, C.; Chauhan, M.; Thota, C. S.; Kondapaka, S.; Wimalawansa, S. J. Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity. Trends Endocr. Metabol. 2002, 13, 263-269.
14. Yallampalli, C.; Gangula, P. R. R.; Kondapaka, S.; Fang, L.; Wimalawansa, S. Regulation of calcitonin gene-related peptide receptors in rat uterus during pregnancy, labor and by progesterone. Biol. Reprod. 1999, 61, 1023-1030.
15. Dong, Y. L.; Fang, L.; Kondapaka, S.; Gangula, P. R. R.; Wimalawansa, S.; Yallampalli, C. Involvement of calcitonin gene-related peptide in the modulation of the human myometrial contraction during pregnancy. J. Clin. Invest. 1999, 104, 559-565.
16. Wisskirchen, F. M.; Burt, R. P.; Marshall, I. Pharmacological caracterization of CGRP receptors mediating relaxation of the rat pulmonary artery and inhibition of twitch responses of the rat vas deferens. Br. J. Pharmacol. 1998, 123, 1673-1683.
17. 2 receptor of the rat prostatic vas deferens. Br. J. Pharmacol. 1999, 126, 1163-1170.
18. Grewal, M.; Cuevas, J.; Chaudhuri, G.; Nathan, L. Effects of CGRP on vascular resistance in rats: role of sex steroids. Am. J. Physiol.: Heart Circ. Physioi 1999, 45, H2063-H2068.
19. Moore, M. C.; Lin, D. W.; Colburn, C. A.; Goldstein, R. E.; Neal, D. W.; Cherrington, A. D. Insulin and glucagon-independent effects of CGRP in the conscious dog. Metab.: Clin. Exp. 1999, 48, 603-610.
20. Shen, Y. T.; Mallee, J. J.; Handt, L. K.; Gilberto, D. B.; Lynch, J. J., Jr.; Hargreaves, R. J.; Koblan, K. S.; Gould, R. J.; Kane, S. A. Effect of inhibition of α-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic hearth failure. J. Cardiovasc. Pharmacol. 2003, 42, 656-661.
21. Diesen, J.; Diener, H. C.; Husstedt, I. W.; Goadsby, P. J.; Hall, D.; Meier, U.; Pollentier, S.; Lesko, L. M. BIBN 4096 BS Clinical Proof of concept Study group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 2004, 350, 1104-1110.
22. Doods, H.; Hallermayer, G.; Dongmei, W.; Entzeroth, M.; Rudolf, K.; Engel, W.; Eberlein, W. Pharmalogical profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 2000, 129, 420-423.
23. Lynch, B.; Kaiser, E. T. Biological properties of two models of calcitonin gene-related peptide with idealized amphiphilic α-helices of different lengths. Biochemistry 1988, 27, 7600-7607.
24. Manning, M. C. Conformation of the alpha form of the CGRP in aqueous solution as determined by circular dichroism spectroscopy. Biochem. Biophys. Res. Commun. 1989, 160, 388-392.
25. 1H NMR and distance geometry with restrained molecular dynamics. Biochemistry 1991, 30, 575-582.
26. Hubbard, J. A. M.; Martin, S. B.; Chaplin, L. C.; Bose, C.; Kelly, S. M.; Price, N. C. Solution structures of calcitonin gene-related peptide analogues of CGRP and amylin. Biochem. J. 1991, 275, 785-788.
27. Boulanger, Y.; Khiat, A.; Chen, Y.; Senécal, L.; Tu, Y.; St Pierre, S.; Fournier, A. Structure of human calcitonin gene-related peptide (hCGRP) and of its antagonist hCGRP 8-37 as determined by NMR and molecular modeling. Pept. Res. 1995, 8, 206-213.
28. Sagoo, J. K.; Bose, C.; Beeley, N. R. A.; Tendler, S. J. B. Structural studies on the [But-Cys18](19-37) fragment of human calcitonin gene-related peptide. Biochem. J. 1991, 280, 147-150.
29. Hakala, J. M. L.; Vihinen, M. Modelling the structure of calcitonin gene-related peptide. Protein Eng. 1994, 7, 1069-1075.
30. Hakala, J. M. L.; Lindvall, M.; Koskinen, A. M. Modelling constrained calcitonin gene-related peptide analogues. Protein Eng. 1996, 9, 143-148.
31. Maggi, C.; Rovero, P.; Giuliani, S.; Evangelista, S.; Regoli, D.; Meli, A. Biological activity of N-terminal fragments of calcitonin gene-related peptide. Eur. J. Pharm. 1990, 179, 217-219.
32. Rovero, P.; Giuliani, S.; Maggi, C. A. CGRP antagonist activity of short C-terminal fragments of human α-CGRP, CGRP(23-37) and CGRP(19-37). Peptides 1992, 13, 1025-1027.
33. Chakder, S.; Rattan, S. [Tyr0]-Calcitonin gene related-peptide 28-37 as a putative antagonist of calcitonin gene related-peptide response on oposum internal anal sphincter smooth muscle. J. Pharmacol. Exp. Ther. 1990, 253, 200-206.
34. Chiba, T.; Yamaguchi, A.; Yamatani, T.; Nakamura, A.; Morishita, T.; Inui, T.; Fukase, M.; Noda, T.; Fujita, T. CGRP receptor antagonist hCGRP (8-37). Am. J. Physiol. 1989, 256, E331-E335.
35. Dennis, T.; Fournier, A.; Cadieux, A.; Pomerleu, F.; Jolicoeur, F. B.; St-Pierre, S.; Quirion, R. hCGRP 8-37 a calcitonin gene-related peptide antagonist revealing CGRP receptor heterogeneity in brain and periphery. J. Pharmacol. Exp. Ther. 1990, 254, 123-128.
36. Maggi, C. A.; Chiba, T.; Giuliani, S. Human a-calcitonin gene related peptide (8-37) as an antagonist of exogenous and endogenous calciton gene-related peptide. Eur. J. Pharmacol. 1991, 192, 85-88.
37. Mimeault, M.; Fournier, A.; Dumont, Y.; St. Pierre, S.; Quirion, R. Comparative affinities and antagonistic potencies of various human CGRP fragments on CGRP receptors in brain and periphery. J. Pharmacol. Exp. Ther. 1991, 258, 1084-1090.
38. 28-37 (rat) as a putative antagonist of CGRP responses on opossum internal and sphincter smooth muscle. J. Pharmacol. Exp. Ther. 1990, 253, 200-206.
39. Rist, B.; Entzeroth, M.; Beck-Sickinger, A. G. From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor. J. Med. Chem. 1998, 41, 117-123.
40. Maton, P. N.; Prandhan, T.; Zhou, Z. C.; Gradner, K. D.; Jensen, R. T. Activities of CGRP and related peptides at the CGRP receptor. Peptides 1990, 11, 485-489.
41. 27-37 analogues with high affinity to the CGRP1 receptor show antagonistic properties in a rat blood flow assay. Regul. Pept. 1999, 79, 153-158.
42. Carpenter, K. A.; Schmidt, R.; Von Mentzer, B.; Haglund, U.; Roberts, E.; Walpole, C. Turn structures in CGRP C-terminal analogues promote stable arrangements of key residue side chains. Biochemistry 2001, 40, 8317-8325.
43. Wisskirchen, F. M.; Doyle, P. M.; Gough, S. L.; Harris, C. J.; Marshall, I. Bioactive beta-bend structures for the antagonist halpha CGRP(8-37) at the CGRP(1) receptor of the rat pulmonary artery. Br. J. Pharmacol. 2000, 129, 1049-1055.
44. Lee, H. J.; Ahn, I. A.; Ro, S.; Choi, K.-H.; Choi, Y. S.; Lee, K. B. Role of azaamino acid residue in beta-turn formation and stability in designed peptide. J. Pept. Res. 2000, 56, 35-46.
45. Lee, H. J.; Choi, K. H.; Ahn, I. A.; Ro, S.; Jang, H. G.; Choi, Y. S.; Lee, K. B. The β-turn preferential solution conformation of a tetrapeptide containing an azaamino acid residue. J. Mol. Struct. 2001, 569, 43-54.
46. Thormann, M.; Hofmann, H. J. Conformational properties of azapeptides. J. Mol. Struct. (THEOCHEM) 1999, 469, 63-76.
47. Lee, H. J.; Song, J. W.; Choi, Y. S.; Park, H. M.; Lee, K. B. A Theoretical Study of Conformational Properties of N-Methyl Azapeptide Derivatives. J. Am. Chem. Soc. 2002, 124, 11881-11893.
48. 1 an Isostere of Bovine Angiotensin II. J. Am. Chem. Soc. 1963, 85, 4040-4041.
49. Niedrich, H. J. Prakt. Chem. 1972, 314, 749.
50. (a) Niedrich, H., Oehme, C. J. J. Prakt. Chem. 1972, 314, 759.
51. (b) Oehme, P.; Bergmann, J.; Falk, M.; Reich, J. G.; Voigt, W. E.; Niedrich, H.; Pirrwitz, J.; Bersek, C.; Jung, F. Acta Biol. Med. Ger. 1972, 28, 109.
52. (c) Oehme, P.; Bergmann, J.; Niedrich, H.; Jung, F.; Menzel, G.; Eichstädt, M. Pharmacology of hydrazine-carbonic acids, hydrazine peptides and other hydrazine derivatives. VII. Pharmacologic studies on heterologous eledoisine sequences. Acta Biol. Med. Ger. 1970, 25, 613-625.
53. (a) Han, H.; Yoon, J.; Janda, K. D. Investigations of azapeptides as mimetics of Leuenkephalin. Biorg. Med. Chem. Lett. 1998, 8, 117-120.
54. (b) Dutta, A. S.; Gormley, J. J.; Hayward, C. F.; Morley, J. S.; Shaw, J. S.; Stacey, G. J.; Turnbull, M. T. Enkephalin analogues eliciting analgesia after intravenous injection. Life Sci. 1977, 21, 559-562.
55. (c) Dutta, A. S.; Gormley, J. J.; Hayward, C. F.; Morley, J. S.; Shaw, J. S.; Stacey, G. J.; Turnbull, M. T. Analgesia following intravenous administration of enkephalin analogues [proceedings]. Br. J. Pharmacol. 1977, 61, 481-482.
56. (a) Ho, T. L.; Nestor, J. J.; Mc Crae, G. I.; Vickery, B. H. Int. J. Pept. Protein Res. 1984, 24, 79.
57. (b) Dutta, A. S.; Furr, B. J. A.; Giles, M. B.; Valcaccia, B.; Walpole, A. L. Potent agonist and antagonist analogues of luliberin containing an azaglycine residue in position 10. Biochem. Biophys. Res. Commun. 1978, 81, 382-390.
58. (c) Furr, B. J. A. Aktuel. Onkol. 1983, 8, 243.
59. (d) Dutta, A. S.; Furr, B. J. A.; Giles M. B.; Valcaccia, B. E. Synthesis and biological activity of highly active alpha-aza analogues of luliberin. J. Med. Chem. 1978, 21, 1018-1024.
60. (e) Dutta, A. S.; Furr, B. J. A. Annu. Rep. Med. Chem. 1985, 20, 203.
61. Zhang, W. J.; Berglund, A.; Kao, J. L. F.; Couty, J. P.; Gershengorn, M. C.; Marshall, J. R. Impact of Azaproline on Amide Cis-Trans Isomerism: Conformational Analyses and NMR Studies of Model Peptides Including TRH Analogues. J. Am. Chem. Soc. 2003, 125, 1221-1235.
62. Lombart, H. G.; Lubell, W. D. Rigid Dipeptide Mimetics. Efficient Synthesis of Enantiopure Indolizidinone Amino Acids. J. Org. Chem. 1996, 61, 9437-9446.
63. Lombart, H. G.; Lubell, W. D. Use of azabicycloalkane amino acids to stabilized β-turn conformations in model peptides and gramicidin S. In Peptides chemistry, structure and biology, Kaumaya, P. T. P.; Hodges, R. S., Eds.; Escom: Leiden, The Netherlands, 1996; p 695.
64. 2aa]. Mémoire de maîtrise, Université de Montréal, 1997.
65. Etzkorn, F. A.; Guo, T.; Lipton, M. A.; Goldberg, S. D.; Bartlett, P. A. Cyclic Hexapeptides and Chimeric Peptides as Mimics of Tendamistat. J. Am. Chem. Soc. 1994, 116, 10412-10425.
66. Nagai, U.; Sato, K.; Nakamura, R.; Kato, R. Bicyclic turned dipeptide (BTD) as a β-turn mimetic; its design, synthesis and incorporation into bioactive peptides. Tetrahedron 1993, 49, 3577-3592.
67. 1-dipeptides in peptide synthesis. J. Am. Chem. Soc. 2004, 126, 6759-6764.
68. DeGrado, W. F.; Kaiser, E. T. Polymer-bound oxime esters as supports for solid-phase peptide synthesis. The preparation of protected peptide fragments. J. Org. Chem. 1980, 45, 1295-1300.
69. Rink, H. Solid-phase synthesis of protected peptide fragments using a trialkoxy-diphenyl-methylester resin. Tetrahedron Lett. 1987, 28, 3787-3790.
70. Boeglin, D.; Lubell, W. D. Aza-amino acid scanning of secondary structure suited for solid-phase peptide synthesis with Fmoc chemistry and aza-amino acids with heteroatomic side chains. J. Comb. Chem. 2005, 7, 864-878.
71. Gilbson, C.; Goodman, S. L.; Hahn, D.; Hölzemann, G.; Kessler, H. Novel Solid-Phase Synthesis of Azapeptides and Azapeptoides via Fmoc-Strategy and Its Application in the Synthesis of RGD-Mimetics. J. Org. Chem. 1999, 64, 7388-7394.
72. Meienhofer, J.; Waki, M.; Heimer, E. D.; Lambros, T. J.; Makofske, R. C.; Chang, C. D. Solid phase synthesis without repetitive acidolysis. Preparation of leucyl-alanyl-glycyl-valine using 9-fluorenylmethyloxycarbonylamino acids. Int. J. Pept. Protein Res. 1979, 13, 35-42.
73. Falb, E.; Yechezkel, T.; Salitra, Y.; Gilon, C. In situ generation of Fmoc-amino acid chlorides using bis-(trichloromethyl) carbonate and its utilization for difficult couplings in solid-phase peptide synthesis. J. Pept. Res. 1999, 53, 507-517.
74. Gosselin, F.; Lubell, W. D. An Olefination Entry for the Synthesis of Enantiopure α,ω-Diamino-dicarboxylates and Azabicyclo[X.Y.0]-alkane Amino Acids. J. Org. Chem. 1998, 63, 7463-7471.
75. Cluzeau, J.; Lubell, W. D. Conformationally Constrained Dipeptide Surrogates with Aromatic Side-Chains: Synthesis of 4-Aryl Indolizidin-9-one Amino Acids by Conjugate Addition to a Common α,ω-Diaminoazelate Enone Intermediate. J. Org. Chem. 2004, 69, 1504-1512.
76. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. L. Color test for Detection of Free Terminal Amino Groups in the Solid-Phase Synthesis of Peptides. Anal. Biochem. 1970, 34, 595-598.
77. Kuwasako, K.; Caoe, Y. N.; Chu, C.-P.; Iwatsubo, S.; Eto, T.; Kitamura, K. Functions of the Cytoplasmic Tails of the Human Receptor Activity-modifying Protein Components of Calcitonin Gene-related Peptide and Adrenomedullin Receptors. J. Biol. Chem. 2006, 281, 7205-7213.
78. Hilairet, S.; Belanger, C.; Bertrand, J.; Laperriere, A.; Foord, S. M.; Bouvier, M. Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin. J. Biol. Chem. 2001, 276, 42182-90.
79. Lang, M.; De Pol, S.; Baldauf, C.; Hofmann, H.-J.; Reiser, O.; Beck-Sickinger, A. G. Identification of the key residue of Calcitonin Gene Related Peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J. Med. Chem. 2006, 49, 616-624.
80. Reynolds, C. H.; Hermann, R. E. Theoretical Study of the Structure and Rotational Flexibility of Diacylhydrazines: Implications for the Structure of Nonsteroidal Ecdysone Agonists and Azapeptides. J. Am. Chem. Soc. 1996, 118, 9395-9401.
81. Lee, H. J.; Lee, M. H.; Choi, Y. S.; Park, H. M.; Lee, K. B. NBO approach to evaluate origin of rotational barrier of diformylhydrazine. J. Mol. Struct. 2003, 631, 101.
82. Thormann, M.; Hofmann, H. J. Conformational properties of azapeptides. J. Mol. Struct. 1999, 469, 63-76.
83. André, F.; Boussard, G.; Bayeul, C.; Didierjean, A.; Aubry, M.; Marraud, M. J. Pept. Res. 1997, 49, 556.